MacDonald Kelvin D, Vesco Kimberly K, Funk Kristine L, Donovan Jerena, Nguyen Thuan, Chen Zunqiu, Lapidus Jodi A, Stevens Victor J, McEvoy Cindy T
Oregon Health and Science University, 3181 SW Sam Jackson Road, Portland, Oregon.
Kasier Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, Oregon.
Pediatr Pulmonol. 2016 Aug;51(8):803-11. doi: 10.1002/ppul.23384. Epub 2016 Jan 21.
Maternal prepregnancy obesity has been associated with early wheeze and childhood asthma in their offspring. Some of these studies have been in minority, urban, and disadvantaged populations using parental recall and questionnaires. The association of maternal prepregnancy obesity with bronchodilator dispensing to their offspring, in a primarily insured, non-urban, White population in the United States is unknown.
We conducted a retrospective cohort study using pharmacy dispensing data from the electronic medical records of a large United States health maintenance organization to examine the relationship between maternal prepregnancy body mass index (BMI) and inhaled bronchodilator dispensing in the offspring to 4 years of age. We included infants ≥37 weeks' gestation with birth weight ≥2.5 kg which yielded 6,194 mother-baby pairs. Maternal prepregnancy BMI was categorized as underweight (<18.5 kg/m(2) ), normal (18.5-24.9 kg/m(2) ), overweight (25-29.9 kg/m(2) ), or obese (≥30 kg/m(2) ).
In the entire cohort, 27.6% of the offspring received a bronchodilator dispensing. This ranged from 19.2% in the offspring of underweight mothers to 31.3% of those born to obese mothers. In the fully adjusted model using normal BMI as the referent, children of obese mothers had a 22% higher rate of bronchodilator dispensing (adjusted OR = 1.22; 95%CI 1.05-1.41; P = 0.008).
In this insured, non-urban, White population, maternal prepregnancy obesity was associated with bronchodilator dispensing in the offspring in early life. These results extend previous data and reaffirm the potential widespread public health impact that prepregnancy obesity may have on subsequent childhood respiratory health. Pediatr Pulmonol. 2016;51:803-811. © 2016 Wiley Periodicals, Inc.
母亲孕前肥胖与后代早期喘息及儿童哮喘有关。其中一些研究针对少数族裔、城市及弱势群体,采用父母回忆及问卷调查的方式。在美国主要为有保险的非城市白人人群中,母亲孕前肥胖与其后代支气管扩张剂的使用之间的关联尚不清楚。
我们进行了一项回顾性队列研究,利用美国一家大型健康维护组织电子病历中的药房配药数据,研究母亲孕前体重指数(BMI)与后代4岁前吸入性支气管扩张剂使用之间的关系。我们纳入了孕周≥37周、出生体重≥2.5千克的婴儿,共得到6194对母婴。母亲孕前BMI分为体重过轻(<18.5千克/平方米)、正常(18.5 - 24.9千克/平方米)、超重(25 - 29.9千克/平方米)或肥胖(≥30千克/平方米)。
在整个队列中,27.6%的后代接受了支气管扩张剂配药。这一比例在体重过轻母亲的后代中为19.2%,在肥胖母亲的后代中为31.3%。在以正常BMI为参照的完全调整模型中,肥胖母亲的孩子支气管扩张剂配药率高22%(调整后的比值比=1.22;95%置信区间1.05 - 1.41;P = 0.008)。
在这个有保险的非城市白人人群中,母亲孕前肥胖与后代早年支气管扩张剂的使用有关。这些结果扩展了先前的数据,并重申了孕前肥胖可能对儿童后续呼吸健康产生的潜在广泛公共卫生影响。《儿科肺科杂志》。2016年;51:803 - 811。©2016威利期刊公司。